RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based therapeutics company founded in 2015 and headquartered in the United States. The company's slogan, "The Science to Overcome Inflammation and Cancer," resonates with its focus on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. RAPT utilizes its proprietary discovery and development engine to create highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. The company has advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4) for the treatment of inflammation and cancer, respectively. Additionally, RAPT is actively pursuing a range of targets that are in the discovery stage of development. Notably, RAPT Therapeutics recently secured a significant $70.50 million Post-IPO Equity investment on 17 November 2022. Though the specific investors were not disclosed, this injection of capital underscores the confidence in RAPT's innovative approach and potential for addressing unmet medical needs in the fields of inflammation and oncology. With its compelling pipeline and focused mission, RAPT Therapeutics stands at the forefront of advancing immunology-based therapeutic solutions.